A seven-metabolite AI model detected renal-cell carcinoma across six validation cohorts
An SVM-based screen of untargeted plasma metabolomics identified candidate renal-cell-carcinoma metabolites, which were confirmed by targeted analysis and used in the RCAID AI diagnostic model. In 1,680 participants across five hospitals, seven plasma metabolites supported AUROCs of 0.977, 0.911, 0.945 and 0.972 in internal, external, multicenter and temporal validation cohorts, respectively; validation also included late-stage and non-clear-cell RCC. The authors report six associated dysregulated pathways from multi-omic analyses.
Technology: Support-vector-machine metabolite selection and the Renal Cell Carcinoma Artificial Intelligence Detector (RCAID)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: An SVM-based screen of untargeted plasma metabolomics identified candidate renal-cell-carcinoma metabolites, which were confirmed by targeted analysis and used in the RCAID AI diagnostic model.
- Still unknown: The study used diagnostic case-control cohorts with healthy controls, so reported discrimination does not establish population-screening performance, clinical utility, or improved outcomes. Most cases were clear-cell RCC (81%) and stage I (69%); subtype and cohort composition may affect generalizability. The abstract reports multi-omic pathway associations but does not establish causal mechanisms. Samples were collected 2019–2023; source publication date is the 2025 online-first date. Source checked; independent replication not assessed.
- AI role: The source states that an SVM was used to identify candidate metabolites from untargeted plasma profiles; targeted metabolomics confirmed selected metabolites. The resulting seven-feature AI-aided RCAID model was evaluated in six independent internal, external, multicenter, temporal, late-stage and non-clear-cell validation cohorts.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41047317/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 83 of works of the same type, year and subfield (OpenAlex work metrics, 8 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.